IUSM Alzheimer's Disease Drug Discovery Center

印第安纳大学医学院阿尔茨海默病药物发现（ADDD）中心的战略目标是整合早期药物发现的复杂能力，并为新出现的阿尔茨海默病（AD）目标假设（超越Ab）的更广泛研究做出贡献，目标是产生新的潜在治疗方法。具体来说，add中心将成为NIA AMP-AD和MODEL-AD计划的战略和运营合作伙伴。通过设计，这将提供药物发现能力，将靶标发现（AMP-AD）的基础工作与基于人类病理学、遗传学和转化生物标志物（MODEL-AD）的AD动物模型中新发现的铅分子连接起来。为了完成add中心的使命，我们汇集了来自印第安纳大学、普渡大学和印第安纳临床与转化科学研究所（CTSI）的世界级科学家和能力团队。该团队在阿尔茨海默病生物学、中枢神经系统药物发现和开发方面拥有丰富的专业知识，并在核心发现技术方面具有卓越的科学水平，这将推动ADDD中心的贡献和成果。拟议的add中心的一个关键优势和差异化优势是通过印第安纳大学医学院进行主要的科学协调和管理。具体来说，通过与nia支持的印第安纳阿尔茨海默病中心（由Andy Saykin博士指导）、模型- ad联盟（由Bruce Lamb博士指导）和纵向早发性阿尔茨海默病（LEAD）研究（由Liana Apostolova博士指导）的共同存在，这集中了对神经退行性研究的强大而长期的承诺。add中心的具体目标是：1。通过对基础研究和新兴疾病认识的重大投资，创建具有良好特征的阿尔茨海默病药物发现目标的动态组合，代表新的干预假设。2. 执行先进的临床前靶点验证和使能研究，优先考虑治疗发现的最佳机会。3. 为满足严格的里程碑标准的优先目标创建高质量和特征良好的先导分子，并为进一步的转化投资提供宝贵的机会。4. 创建一个强大而灵活的数据共享平台，使全球研究人员能够使用数据和目标启用包来扩展add CENTER的工作。

The strategic goal of the Indiana University School of Medicine Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s disease (AD) target hypotheses (beyond Ab) with the goal of generating new classes of potential therapeutics. Specifically, the ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a world-class team of scientists and capabilities from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer’s Disease Center under the direction of Dr. Andy Saykin, the MODEL-AD consortium under the direction of Dr. Bruce Lamb, and the Longitudinal Early Onset Alzheimer’s Disease (LEAD) study under the direction of Dr. Liana Apostolova. The Specific Aims of the ADDD CENTER are: 1. Create a dynamic portfolio of well-characterized AD drug discovery targets representing novel intervention hypotheses that capitalize on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create high-quality and well-characterized lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment. 4. Create a robust and flexible data sharing platform to enable global researchers with data and target enablement packages to expand on the work of the ADDD CENTER.